These results showed modest venetoclax efficacy, but Bcl-2 family protein analysis and BH3 profiling showed that AML blast Bcl-2 upregulation and dependence varied in these patients, suggesting that venetoclax could work better with a combination regimen [60]. Here, BCL2 is linked to acute myeloid leukemia.